Results 1 to 10 of about 9,343 (120)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study

BMC Rheumatology, 2023
Background Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators.
Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis   +9 more
doaj   +1 more source

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Arthritis Research & Therapy, 2022
Background Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatologic
M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh   +8 more
doaj   +1 more source

Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting

Drugs - Real World Outcomes, 2022
Background The efficacy and safety of golimumab in elderly patients with renal dysfunction are not well evaluated due to the exclusion criteria of clinical trials.
Seiji Yokoyama, Yutaka Ishii, Junya Masuda   +2 more
doaj   +1 more source

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Advances in Rheumatology, 2023
Background In patients with rheumatic diseases, the use of biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) after discontinuation of tumor necrosis factor inhibitors (TNFi) is known to be effective.
Manuel Pombo-Suárez, Daniel Seoane-Mato, Federico Díaz-González, Fernando Sánchez-Alonso, Marta Sánchez-Jareño, Luis Cea-Calvo, Isabel Castrejón   +6 more
doaj   +1 more source

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study

Rheumatology and Therapy, 2023
Introduction To assess changes in the Patient-Reported Outcomes Measurement Information System (PROMIS®) outcomes related to social, mental, and physical well-being after approximately 1 year of intravenous (IV) golimumab or infliximab treatment in ...
Clifton O. Bingham, Shawn Black, Natalie J. Shiff, Stephen Xu, Wayne Langholff, Jeffrey R. Curtis   +5 more
doaj   +1 more source

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Arthritis Research & Therapy, 2020
Background In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression.
Philip Mease, M. Elaine Husni, Shelly Kafka, Soumya D. Chakravarty, Diane D. Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Arthur Kavanaugh   +8 more
doaj   +1 more source

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Therapeutic Advances in Gastroenterology, 2022
Background: Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study
Kathrin Perrig, Niklas Krupka, Sebastian Bruno Ulrich Jordi, Jean-Benoît Rossel, Luc Biedermann, Thomas Greuter, Philipp Schreiner, Stephan R. Vavricka, Pascal Juillerat, Emanuel Burri, Dorothee Zimmermann, Michel H. Maillard, Michael Christian Sulz, Stephan Brand, Gerhard Rogler, Benjamin Misselwitz   +15 more
doaj   +1 more source

Sobrevida, eficacia y seguridad de Golimumab en pacientes con Artritis Reumatoidea y Espondiloartritis: datos de una cohorte argentina

Revista Argentina de Reumatología, 2021
Objetivos: golimumab ha sido aprobado para el tratamiento de pacientes con artritis reumatoidea (AR), artritis psoriásica (APs) y espondiloartritis axial. Sin embargo, los datos provenientes de nuestra región son escasos. El objetivo de este estudio fue
Carolina A. Isnardi, Emma Civit, Agustín García Ciccarelli, Jimena Sánchez Alcover, Sebastián Magri, Rodrigo García Salinas, Eduardo Albiero, Carla Gobbi, Edson Velozo, Enrique R. Soriano, Martín Brom, Johana Zacariaz, Ingrid Strusberg, Marcos Baravalle, Sol Castaños, Liliana Morales, Sergio Paira, Romina Calvo, Alberto Ortiz, Rodolfo Pérez Alamino, Hernán Maldonado Ficco, Gustavo Citera   +21 more
doaj   +1 more source

Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan

Therapeutic Advances in Drug Safety, 2019
Background: The golimumab safety awareness study commenced in 2010 to measure, periodically, the awareness of golimumab prescriber healthcare professionals (HCPs) of specific risks associated with golimumab as well as awareness of the requirement to ...
Lauren Felo, Marijo Otero-Lobato, Anja Geldhof, Wim Noël   +3 more
doaj   +1 more source

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS

Вопросы современной педиатрии, 2012
The article represents the results of efficacy and safety evaluation of the human monoclonal antibodies — golimumab, according to the data of international multicenter randomized double-blind placebo-controlled trials, including patients with active ...
R. V. Denisova, E. I. Alexeeva
doaj   +1 more source